Pharmacokinetics and Bioequivalence of two Empagliflozin Tablet Formulations: Results From a Randomized, Open‐Label, Crossover Study in Fasting Healthy Volunteers
Clinical Pharmacology in Drug Development · 2026
DOI: 10.1002/cpdd.1614 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Kar Ming Yee und 10 weiteren Autor:innen. Beteiligte Einrichtung: Formulation and R&D Technologies, Duopharma Innovation Sdn. Bhd., Shah Alam, Malaysia. Hauptthemen laut MEDLINE: Glucosides, Benzhydryl Compounds, Sodium-Glucose Transporter 2 Inhibitors, Drugs, Generic. Die Arbeit nennt 21 Literaturangaben. Gefördert von: Duopharma Biotech Berhad fund.
Abstract (Originalsprache)
This study aimed to assess the bioequivalence of a newly developed generic formulation of empagliflozin in comparison with the reference product. A total of 32 healthy adult volunteers participated in an open‐label, randomized, balanced, two‐treatment, two‐sequence, two‐period crossover study. Following an overnight fast, each participant received a 25 mg single oral dose of either the test or the reference empagliflozin with a 1‐week washout period between treatments. Safety was monitored throughout the study, and 21 blood samples were collected at pre‐dose and at multiple time points from 0.5 to 48 h post‐dose. Plasma concentrations of empagliflozin were quantified using a validated LCMS/MS method following liquid–liquid extraction. Pharmacokinetic parameters were calculated using non‐compartmental analysis and statistically compared between formulations using multivariate analysis of variance. The test formulation was well tolerated under fasting conditions, with no serious adverse events reported. The pharmacokinetic parameters, including C max and AUC 0– t , were not significantly different between the test and reference products. The 90% confidence intervals of the Ln‐transformed pharmacokinetic parameters fell within the bioequivalence acceptance range of 80.00% to 125.00%. In conclusion, the test and reference formulations of empagliflozin 25 mg are bioequivalent under fasting conditions in healthy individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Formulation and R&D Technologies, Duopharma Innovation Sdn. Bhd., Shah Alam, Malaysia.
- Clinical Research & Biosciences Division, Cohance Lifesciences Limited (Clinical Research & Biosciences Division), Hyderabad, India.
Förderung
- Duopharma Biotech Berhad fund
Zitieren
APA
Yee, K. M., Sagim, E., Leong, C. W., Liew, I., Mahathar, M. N., Zulhuda, N. A., Ahmad, S., Baharin, N. A., Miryala, N., Gaddamedi, N., & Yarramshetti, V. K. (2026). Pharmacokinetics and Bioequivalence of two Empagliflozin Tablet Formulations: Results From a Randomized, Open‐Label, Crossover Study in Fasting Healthy Volunteers. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1614
Vancouver
Yee KM, Sagim E, Leong CW, Liew I, Mahathar MN, Zulhuda NA, et al. Pharmacokinetics and Bioequivalence of two Empagliflozin Tablet Formulations: Results From a Randomized, Open‐Label, Crossover Study in Fasting Healthy Volunteers. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.1614
BibTeX
@article{Yee2026,
author = {Yee, Kar Ming and Sagim, Elton and Leong, Chuei Wuei and Liew, Ivan and Mahathar, Muhammad Najib and Zulhuda, Nurul Anis and Ahmad, Shahnun and Baharin, Nida Asnida and Miryala, Narender and Gaddamedi, Narender and Yarramshetti, Viresh Kumar},
title = {Pharmacokinetics and Bioequivalence of two Empagliflozin Tablet Formulations: Results From a Randomized, Open‐Label, Crossover Study in Fasting Healthy Volunteers},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
doi = {10.1002/cpdd.1614}
}
EUVIMED